Tsai Capital Corp Buys 522 Shares of Zoetis Inc. (NYSE:ZTS)

Tsai Capital Corp raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,492 shares of the company’s stock after acquiring an additional 522 shares during the quarter. Zoetis makes up approximately 1.7% of Tsai Capital Corp’s holdings, making the stock its 22nd largest position. Tsai Capital Corp’s holdings in Zoetis were worth $2,361,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC grew its position in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the period. Rakuten Securities Inc. boosted its stake in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the period. Murphy & Mullick Capital Management Corp purchased a new stake in Zoetis in the fourth quarter worth about $44,000. Finally, Asset Planning Inc purchased a new position in shares of Zoetis during the fourth quarter valued at approximately $58,000. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of recent research reports. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Finally, UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Trading Down 1.2 %

Shares of Zoetis stock opened at $163.03 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock has a market capitalization of $73.00 billion, a PE ratio of 29.80, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The company’s fifty day simple moving average is $166.40 and its 200-day simple moving average is $174.67.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.